Skip to main content
ERC
News
Participate
Patients
Doctors
Investors
Products
Gliovac/ERC1671
Media
News
Publications
About
Executive Management
Executive board
Scientific board
Milestone achievements
Contact
News
Publications
07
Apr
2021
ERC-USA Announces FDA Recommendation for Early Termination of Phase 2 Clinical Trial of ERC1671 (Gliovac or Sitoiganap) and Application for Registration Trial for Treatment of Glioblastoma
24
Dec
2020
CEO STATEMENT 2020/2021
26
Jun
2020
ERC Belgium, has submitted to the EMA(European Medicines Agency) its Marketing Authorization Application (MAA) for conditional approval of its lead product Gliovac/ERC1671/SITOIGANAP to treat recurrent glioblastoma (GBM).
01
May
2020
ERC receives a positive Opinion to commence a paediatric investigation plan(clinical trial) from the European Medicines Agency.
30
Apr
2020
12 Month Progress Report 30/04/2019-30/04/2020
24
Apr
2020
ERC Launches Development Program for Novel Cell-Based Therapeutic and Prophylactic SARS-CoV-2 Vaccine
20
Apr
2020
LATEST SITUATION – CEO STATEMENT
09
Apr
2020
ERC covid product launch against covid19
01
Apr
2020
In Q2 2020 after enrolling about 40 patients in the Phase II clinical trial, ERC will submit its request for commercialization in the USA
23
Mar
2020
Do Academics kill more patients than the disease?
27
Dec
2019
Abigail-Alliance Humanitarian of the year award 2019
In recognition of ERC’s commitment, Doctor Stathopoulos has received the Abigail-Alliance award for Humanitarian of the year 2019 for the ERC RTT program and Gliovac/ERC1671. Click...
27
Feb
2019
Decision of National organisation of Medicines of Greece
Issue: CU-10/JAN/2019
Approval of Temporary Individual Access to Early Access to the Medicinal Product GLIOVAC in Greece.
31
Aug
2018
12 month progress report 31/08/2017-31/09/2018
ERC has made significant progress over the past 12 months in moving our experimental vaccine Gliovac (also know as ERC1671) toward commercialization.
08
Jul
2016
New production site in the Netherlands
ERC has opened a new additional production site in the Netherlands dedicated to GMP-based production of Gliovac/ERC1671 against glioblastoma brain cancer, as well as vaccines based on the same,...
15
May
2016
Approval for open phase II study
ULB Belgium’s ethical commitee has approved the protocol for an open phase II study of standard treatments in combination
with Gliovac/ERC1671
vs
standard treatments
...
Pages
1
2
last »
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our
cookies information
for more details.
Close